BIOMARKER tracker continued — pSer65-Ub MJ assay (Atalee + SMC4Ps + Boston Bioscience LSBio antibody), MITOKININ NBB CSF, BoMM 240 NBB samples, NLM newsletter PhanoSwitch saliva-EV proteomics, Korean RDDDU/OCT decision note
BIOMARKER tracker (continued)
(Continuation of biomarker development tracker rows from 20240722_182644. The full per-row content is preserved in format_notes; key visible items are reproduced below.)
pSer65-Ub MJ assay updates
| date / row | content |
|---|---|
| 20210419 Otake | (status update) |
| 20210419 Kanaguchi | (collaboration note) |
| 20210624 OAS Hatano | collaboration with Hatano-san |
| 20210910 | Detection of Sci eluate using Atalee Itsis pSer65-Ub from PSer65-Ub from Sci pulled-down samples is feasible. Quantification of Atalee samples will be performed by end of Q3 |
| Reagent | source |
|---|---|
| Boston Bioscience Phospho-Ubiquitin (pS65)-LinkA Antibody | LSBio Cat# PA5-115716, Cat# 5215115 ELLet, S2120, 525117 (S2120) |
pSer65-Ub assay sensitivity / quantitation
- 20210907 MJ: A highly sensitive pS65-Ub assay using SMC4Ps instrument was started in May. The assay feasibility will be available by the end of June and clinical sample feasibility assessment will be performed by end of Q3.
- 20210914 (we just got preliminary feedback at pS65 assay sensitivity using SMC4Ps). The result was positive, achieved 30 and 25 times higher sensitivity than the prior method respectively.
- 20210914 BFA assay value initialization start cyno serum + Pooled in cyno plasma + start LCMS instrument achieved buffer-based LCQ 1.5 nM, but spike rim 0.5 ng/ml takes 12 sample volumes.
- 20210910 PSer65-Ub method evaluation using human CSF is on-going. PSer65-Ub assay sensitivity is approved on Patient sample enrichment process can be applied.
- 20211228 While reproducibility of spike-recovery in human CSF was confirmed in the established SMC4Ps assay (1Lif), DLP shows in human CSF (Parkin lambda group of antibody assay was not detected from pulsed normal CSF. To solve this issue, some sample enrichment process will be applied.
- 20211129 We finally detected pS65-Ub from pooled human CSF samples. The concentration is comparable than expected.
MITOKININ NBB CSF
MITOKININ result: TO confirms the feasibility with NBB CSF sample (4). Mice not continued. Will continue to improve the assay accuracy in close concentration range. To confirm whether we can detect from new CSF samples (we should concentrate CSF samples).
BoMM 240 — NBB samples
| Sample | Test | Goal | Sample | Outcomes |
|---|---|---|---|---|
| parameters expression assessment in NBB samples for drug discovery and validation |
(rationale & proposal for development)
From 30/120/202 NLM newsletter, Research proposal was approved by a connection in NBB and they can provide 5 ml saliva from 23 PD patients and 27 control subjects from BioFIND cohort. Total saliva and saliva-EV fraction will be evaluated on LCMS-based proteomics in PhanoSwitch. MTA contracting is underway.
Survey of available external options and/or partnerships → Vendor or internal SCM12 8
| Vendor/collaborator | the Privilege Assessments → Candidate IMG. | SMS for use within Takeda 4) (5/L) (5/L) | Synonym (R) (R/I) | Technical characterizes us all marker is irrelevant population (R/L) |
|---|
A) Atrophy ((cf wax & lipid accumulation), or how mice must have lipid accumulation? Retina vs midbrain?
- PLR과 무관리, Tomimatsu와 무관리, OCT 개발본으로, histology 시행 → RDDDU는 그들 Tx (rhGCB)가 GlcSph 올라서 D409V 안 쓸건데? 그래도 우리 Tx (GBA GT, AC i)가 줄이면 되겠어? 아니 Tx response 이전에 model 확립 필요 → RDDDU가 Histology 못한다고 하면, oct 위해 안과의사 만나야 겠네.
- Oxygen consumption: BM Discovery 문헌은 없음, assay 개발후 (PFA로) in vitro